ub-vv400
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2024 (NCT06743503)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06743503 | Phase 1 | Dec 31, 2024 | IASO Pharma Inc., Nanjing Medical University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IASO Pharma Inc. | For profit | 1 | 1 | 1 | 2024 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1